BioCryst Pharmaceuticals (NASDAQ:BCRX) Lifted to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a sell rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports.

According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “

A number of other research firms have also weighed in on BCRX. Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 3rd. They set an overweight rating and a $21.00 price target on the stock. JMP Securities reiterated a buy rating and issued a $23.00 target price on shares of BioCryst Pharmaceuticals in a report on Thursday, September 16th. Cowen boosted their target price on shares of BioCryst Pharmaceuticals from $18.00 to $21.00 and gave the company an outperform rating in a report on Thursday, June 17th. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $20.00 to $21.00 and gave the company an overweight rating in a report on Friday, August 6th. Finally, Piper Sandler boosted their target price on shares of BioCryst Pharmaceuticals from $18.00 to $22.00 and gave the company an overweight rating in a report on Thursday, August 5th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Buy and an average target price of $20.80.

BCRX stock opened at $14.99 on Wednesday. The stock has a market capitalization of $2.68 billion, a P/E ratio of -12.49 and a beta of 2.59. The firm has a 50-day simple moving average of $15.21 and a 200-day simple moving average of $14.54. BioCryst Pharmaceuticals has a 52 week low of $3.46 and a 52 week high of $18.48.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Thursday, August 5th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $49.96 million for the quarter, compared to analyst estimates of $31.37 million. BioCryst Pharmaceuticals had a negative return on equity of 5,272.40% and a negative net margin of 270.53%. On average, equities research analysts expect that BioCryst Pharmaceuticals will post -1.22 earnings per share for the current year.

In related news, Director George B. Abercrombie sold 74,000 shares of the stock in a transaction on Friday, September 10th. The shares were sold at an average price of $15.09, for a total value of $1,116,660.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 4.80% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Thrivent Financial for Lutherans acquired a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth $1,826,000. Virtu Financial LLC acquired a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth $540,000. Parametric Portfolio Associates LLC boosted its stake in BioCryst Pharmaceuticals by 117.4% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 220,014 shares of the biotechnology company’s stock worth $3,478,000 after purchasing an additional 118,825 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth $170,000. Finally, Morgan Stanley boosted its stake in BioCryst Pharmaceuticals by 254.7% during the 2nd quarter. Morgan Stanley now owns 912,205 shares of the biotechnology company’s stock worth $14,423,000 after purchasing an additional 654,998 shares during the period. Hedge funds and other institutional investors own 58.33% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company, which engages in the development and discovery of novel, oral, and small-molecule medicines. It focuses on the oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease.

Featured Article: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.